A phase I trial of an interleukin‐12/23 monoclonal antibody in relapsing multiple sclerosis

References

• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. New Engl J Med 2000;343:938–52
   PubMed Web of Science ®Google Scholar
• Burks J, Johnson K. Multiple sclerosis: diagnosis, medical management and rehabilitation. New York: Demos Medical Publishing, Inc.; 2000
   Google Scholar
• Freedman MS, Patry DG, Grand’Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31:157–68
   Google Scholar
• Rovaris M, Filippi M. Interventions for the prevention of brain atrophy in multiple sclerosis: current status. CNS Drugs 2003;17:563–75
   PubMed Web of Science ®Google Scholar
• Ebers GC and the PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352: 1498–504
   Google Scholar
• Sibley WA and the IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45: 1277–85
   Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing–remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268–76
   PubMed Web of Science ®Google Scholar
• Segal BM, Dwyer BK, Shevach EM. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J Exp Med 1998;187: 537–46
   Google Scholar
• Windhagen A, Newcombe J, Dangond F, et al. Expression of costimulatory molecules B7–1 (CD80), B7–2 (CD86) and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985–96
   PubMed Web of Science ®Google Scholar
• Van Boxel-Dezaire AH, Hoff SC, van Oosten BW, et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999;45: 695–703
   Google Scholar
• Nicoletti F, Patti F, Cocuzza C, et al. Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. J Neuroimmunol 1996;70:87–90
   PubMed Web of Science ®Google Scholar
• Fassbender K, Ragoschke A, Rossol S, et al. Increased release of interleukin-12p40 in MS: association with intracerebral inflammation. Neurology 1998;51:753–8
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13: 715–25
   PubMed Web of Science ®Google Scholar
• Becher B, Durell BG, Noelle RJ. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J Clin Invest 2003;112;1186–91
   Google Scholar
• Gran B, Zhang GX, Yu S, et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol 2002;169:7104–10
   PubMed Web of Science ®Google Scholar
• Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744–8
   PubMed Web of Science ®Google Scholar
• Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med 1995;181: 381–6
   Google Scholar
• Brok HP, van Meurs M, Blezer E, et al. Prevention of experimental autoimmune encephalomyelitis in common marmosets using an IL-12/23 mAb monoclonal antibody. J Immunol 2002;169:6554–63
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–7
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC, for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907–11
   Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52
   PubMed Web of Science ®Google Scholar
• Sipe JC, Knobler RL, Braheny SL, et al. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34: 1368–72
   PubMed Web of Science ®Google Scholar
• Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46: 1121–3
   Google Scholar
• Schwartz CE, Vollmer T, Lee H, North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 1999;52: 63–70
   Google Scholar
• Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999;122:871–82
   PubMed Web of Science ®Google Scholar
• Arnason BGW, Jacobs G, Hanlon M, et al. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457–65
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002;16:183–200
   PubMed Web of Science ®Google Scholar